IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Nissay Asset Management Corp Japan ADV

Nissay Asset Management Corp Japan ADV raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 18,688 shares of the company's stock after purchasing an additional 698 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in IDEXX Laboratories were worth $7,754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth $31,000. Colonial Trust Co SC increased its position in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the last quarter. Finally, Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $38,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus lifted their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday. Finally, Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $3.58 during trading on Monday, reaching $521.68. The company had a trading volume of 427,581 shares, compared to its average volume of 648,845. The firm's fifty day moving average is $431.28 and its 200 day moving average is $431.45. The firm has a market capitalization of $41.95 billion, a PE ratio of 48.89, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $545.43. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.71 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.